Your browser doesn't support javascript.
loading
Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?
García-Escobar, I; Beato-Zambrano, C; Muñoz Langa, J; Brozos Vázquez, E; Obispo Portero, B; Gutiérrez-Abad, D; Muñoz Martín, AJ.
Afiliação
  • García-Escobar, I; Hospital General Universitario de Ciudad Real. Medical Oncology. Ciudad Real. Spain
  • Beato-Zambrano, C; Hospital Universitario Virgen Macarena. Medical Oncology GU and Breast Cancer Department. Seville. Spain
  • Muñoz Langa, J; Hospital Universitario La Fe. Medical Oncology. Valencia. Spain
  • Brozos Vázquez, E; Hospital Clínico Universitario de Santiago de Compostela. Medical Oncology. Santiago de Compostela. Spain
  • Obispo Portero, B; Hospital Universitario Infanta Leonor. Medical Oncology. Madrid. Spain
  • Gutiérrez-Abad, D; Hospital Universitario de Fuenlabrada. Medical Oncology. Fuenlabrada. Spain
  • Muñoz Martín, AJ; Hospital General Universitario Gregorio Marañón. Medical Oncology. Madrid. Spain
Clin. transl. oncol. (Print) ; 20(9): 1097-1018, sept. 2018. tab
Article em En | IBECS | ID: ibc-173694
Biblioteca responsável: ES1.1
Localização: BNCS
ABSTRACT
The association between venous thromboembolism (VTE) and cancer has been recognized for more than 100 years. Numerous studies have been performed to investigate strategies to decrease VTE incidence and to establish whether treating VTE impacts cancer progression and overall survival. Accordingly, it is important to understand the role of the hemostatic system in tumorigenesis and progression, as there is abundant evidence associating it with cell survival and proliferation, tumor angiogenesis, invasion, and dissemination, and metastasis formation. In attempts to further the scientific evidence, several studies examine survival benefits in cancer patients treated with anticoagulant therapy, specifically treatment with vitamin K antagonists, unfractionated heparin, and low-molecular-weight heparin. Several studies and meta-analyses have been conducted with a special focus on brain tumors. However, no definitive conclusions have been obtained, and more well-designed clinical trials are needed
RESUMEN
No disponible
Assuntos
Buscar no Google
Coleções: 06-national / ES Base de dados: IBECS Assunto principal: Heparina / Anticoagulantes / Neoplasias Limite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Ano de publicação: 2018 Tipo de documento: Article
Buscar no Google
Coleções: 06-national / ES Base de dados: IBECS Assunto principal: Heparina / Anticoagulantes / Neoplasias Limite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Ano de publicação: 2018 Tipo de documento: Article